Open AccessOvercoming Taxane and Anthracycline Resistance
Author(s) -
Zelnak Amelia
Publication year - 2010
Publication title -
the breast journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.533
H-Index - 72
eISSN - 1524-4741
pISSN - 1075-122X
DOI - 10.1111/j.1524-4741.2010.00911.x
Subject(s) - epothilones , medicine , taxane , ixabepilone , anthracycline , drug resistance , adjuvant , paclitaxel , pharmacology , efflux , drug , epothilone , oncology , mechanism (biology) , breast cancer , cancer , cancer research , metastatic breast cancer , biology , philosophy , chemistry , genetics , epistemology , microbiology and biotechnology , combinatorial chemistry
With more and more breast cancer (BC) patients receiving taxanes and anthracyclines in the adjuvant setting, the number of patients resistant to these drugs is rising. Herein, we review cellular mechanisms (e.g., overexpression of drug efflux pumps) that are associated with clinical anthracycline and/or taxane‐resistant BC. We also discuss therapeutic approaches that have received Food and Drug Administration approval in this setting or are in clinical development, including targeted agents that do not employ a cytotoxic mechanism, as well as novel chemotherapeutics such as the epothilones, a class of microtubule stabilizers less susceptible to common cellular resistance mechanisms.